Change in Antithyroglobulin Antibody Levels is a Good Predictor of Responses to Therapy in Antithyroglobulin Antibody-Positive Pediatric Papillary Thyroid Carcinoma Patients
Table 6
Clinicopathologic factors associated with the TgAb trend.
No. of patients
Decrease ≥50%
Decrease <50% or increase
p
Age at diagnosis of DTC
≤15
13 (27.08%)
7 (24.14%)
6 (31.58%)
0.571
>15
35 (73.93%)
22 (75.86%)
13 (68.42%)
Sex
Female
44 (91.67%)
26 (89.66%)
18 (94.74%)
1.000
Male
4 (8.3%)
3 (10.34%)
1 (5.26%)
Tumor diameter (cm)
≤2
24 (50.0%)
17 (58.62%)
7 (36.84%)
0.227
>2, ≤4
16 (33.33%)
9 (31.03%)
7 (36.84%)
>4
8 (16.67%)
3 (10.34%)
5 (26.32%)
Multiplicity
Single
26 (54.17%)
17 (58.62%)
9 (47.37%)
0.444
Multiple
22 (45.83%)
12 (41.38%)
10 (52.63%)
Extra-thyroidal extension
No
31(64.58%)
24 (82.76%)
7 (36.84%)
<0.001
Minimal/gross
17(35.42%)
5 (17.24%)
12 (63.16%)
N stage
N0 or Nx
4 (8.33%)
2 (6.90%)
2 (10.53%)
0.062
N1a
11 (22.92%)
10 (34.48%)
1 (5.26%)
N1b
33 (68.75%)
17 (56.62%)
16 (84.21%)
Distant metastases
No
45 (93.75%)
29 (100.0%)
16 (84.21%)
0.056
Yes
3 (6.25%)
0 (0%)
2 (15.79%)
Initial risk stratification
Low
7 (14.58%)
5 (17.24%)
2 (10.53%)
<0.001
Intermediate
19 (39.58%)
17 (58.62%)
2 (10.53%)
High
22 (45.83%)
7 (24.14%)
15 (78.95%)
With LT
No
25 (52.08%)
14 (48.28%)
11 (57.89%)
0.514
Yes
23 (47.92%)
15 (51.72%)
8 (42.11%)
Number of courses for 131I therapy
1
40 (83.33%)
25 (86.21%)
15 (78.95%)
0.695
>1
8 (16.67%)
4 (13.79%)
4 (21.05%)
Cumulative dose of 131I activities (mCi)
≤100
37 (77.08%)
24 (82.76%)
13 (68.42%)
0.304
>100
11 (22.92%)
5 (17.24%)
6 (31.58%)
Suppressed Tg at first follow-up after RAI therapy
